05:13 PM EDT, 05/23/2024 (MT Newswires) -- Eupraxia Pharmaceuticals Inc. ( EPRX ) , a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, after trade Thursday announced that regulators in Australia and Canada have cleared the company's request to expand its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis.

A statement noted "the recently disclosed clinical data from initial low-dose cohorts showing signs of potential efficacy, as well as encouraging safety and duration of impact from EP-104GI, support the significant expansion of the RESOLVE trial as a pathway to a potential registration trial commencing in 2025."

"We are excited about the data to date from the RESOLVE trial, particularly the patient responses and the extended duration of effect," said Dr. James Helliwell, Chief Executive Officer. "Our DiffuSphere delivery technology is a supporting factor for this opportunity for higher dosing, which could result in a longer duration of efficacy and more profound patient improvement. We believe that the encouraging data seen in patients in our lowest-dose cohorts opens the door, with this amendment, to develop a potentially efficacious annual therapy with a strong safety profile for patients suffering with EoE."

The company said it intends to continue to periodically disclose additional data from the trial.